Close Menu

NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Thursday that its third quarter revenues rose 74 percent year over year, thanks largely to a 105 percent increase in testing services revenues.

For the three months ended Sept. 30, the diagnostics company said revenues rose to $21.2 million from $12.2 million in Q3 2017, beating analysts' average estimate of $18.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.